Moreover, we have previously identified LCS1269 as a potential anti-glioblastoma agent, probably interfering with cell cycle regulation through both direct CDK1 inhibition and indirect modulation of CDK1 activity through Wee1/Myt1 and FOXM1/Plk1 signaling pathways [20]. This evidence concerns the gene MYT1 and glioblastoma.